CADL
NASDAQ · Biotechnology
Candel Therapeutics Inc
$8.33
-0.32 (-3.70%)
Open$8.56
Previous Close$8.65
Day High$8.61
Day Low$8.16
52W High$14.00
52W Low$4.35
Volume—
Avg Volume1.11M
Market Cap669.54M
P/E Ratio—
EPS$-1.41
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+471.3% upside
Current
$8.33
$8.33
Target
$47.59
$47.59
$33.44
$47.59 avg
$47.92
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.25M | 41.90M | 41.45M |
| Net Income | -4,564,062 | -5,052,559 | -4,078,464 |
| Profit Margin | -10.1% | -12.1% | -9.8% |
| EBITDA | -6,328,796 | -6,835,485 | -6,691,447 |
| Free Cash Flow | -4,822,512 | -5,572,664 | -3,889,078 |
| Rev Growth | -8.7% | -6.2% | +3.8% |
| Debt/Equity | 0.84 | 0.77 | 1.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |